LGALS3 and lung carcinoma: Our observation of decreased GAL3 expression following FNE treatment (Supplementary information, Figure 1c) aligns with the notion that targeting GAL3 may hold therapeutic promise in lung cancer management (Kusuhara et al., 2021[26]; Torres‐Martínez et al., 2024[47]).